Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Nurix Therapeutics, Inc., Kymera Therapeutics or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Nurix Therapeutics, Inc., Kymera Therapeutics and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Nurix Therapeutics, Inc., Kymera Therapeutics and Inc.

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Latest Biotechnology and Nurix Therapeutics, Inc., Kymera Therapeutics, Inc. Stock News

As of June 12, 2026, Nurix Therapeutics, Inc. had a $1.8 billion market capitalization, compared to the Biotechnology median of $246.7 million. Nurix Therapeutics, Inc.’s stock is down 10.6% in 2026, up 15.8% in the previous five trading days and up 34.2% in the past year.

Currently, Nurix Therapeutics, Inc. does not have a price-earnings ratio. Nurix Therapeutics, Inc.’s trailing 12-month revenue is $71.8 million with a -411.4% net profit margin. Year-over-year quarterly sales growth most recently was -65.9%. Analysts expect adjusted earnings to reach $-2.353 per share for the current fiscal year. Nurix Therapeutics, Inc. does not currently pay a dividend.

As of June 12, 2026, Kymera Therapeutics, Inc. had a $7.1 billion market cap, putting it in the 73rd percentile of all stocks. Kymera Therapeutics, Inc.’s stock is up 10.8% in 2026, up 16.3% in the previous five trading days and up 78.15% in the past year.

Currently, Kymera Therapeutics, Inc. does not have a price-earnings ratio. Kymera Therapeutics, Inc.’s trailing 12-month revenue is $51.5 million with a -611.9% net profit margin. Year-over-year quarterly sales growth most recently was 55.7%. Analysts expect adjusted earnings to reach $-3.532 per share for the current fiscal year. Kymera Therapeutics, Inc. does not currently pay a dividend.

How We Compare Nurix Therapeutics, Inc., Kymera Therapeutics and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Nurix Therapeutics, Inc., Kymera Therapeutics and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Nurix Therapeutics, Inc., Kymera Therapeutics and Inc.’s Quality Grades

Company	Ticker	Quality
Nurix Therapeutics, Inc.	NRIX	F
Kymera Therapeutics, Inc.	KYMR	D

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

Nurix Therapeutics, Inc. has a Quality Score of 5, which is Very Weak. Kymera Therapeutics, Inc. has a Quality Score of 33, which is Weak.

The Quality Stock Winner: No Clear Winner

Neither Nurix Therapeutics, Inc., Kymera Therapeutics or Inc. has a high enough Quality Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Nurix Therapeutics, Inc., Kymera Therapeutics or Inc. is the better investment when it comes to quality.

Nurix Therapeutics, Inc., Kymera Therapeutics and Inc.’s Momentum Grades

Company	Ticker	Momentum
Nurix Therapeutics, Inc.	NRIX	A
Kymera Therapeutics, Inc.	KYMR	A

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Nurix Therapeutics, Inc. has a Momentum Score of 81, which is Very Strong. Kymera Therapeutics, Inc. has a Momentum Score of 83, which is Very Strong.

The Momentum Grade Winner: It’s a Tie!

Looking at the Momentum Grade breakdown above, both Nurix Therapeutics, Inc., Kymera Therapeutics and Inc. have a grade of A. For those who focus solely on a company’s momentum, further research will need to be conducted into both companies to see if they fit your individual needs as an investor.

Nurix Therapeutics, Inc., Kymera Therapeutics and Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Nurix Therapeutics, Inc.	NRIX	B
Kymera Therapeutics, Inc.	KYMR	C

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Nurix Therapeutics, Inc. has a Earnings Estimate Score of 63, which is Positive. Kymera Therapeutics, Inc. has a Earnings Estimate Score of 50, which is Neutral.

The Earnings Estimate Revisions Grade Winner: Nurix Therapeutics, Inc.

As you can clearly see from the Earnings Estimate Revisions Grade breakdown above, Nurix Therapeutics, Inc. has a better Earnings Estimate Revisions Grade than Kymera Therapeutics, Inc.. For those who are specifically looking for companies with better short-term prospects when compared to other companies in the same industry, Nurix Therapeutics, Inc. could be a good stock to invest in. However, it’s important to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Nurix Therapeutics, Inc., Kymera Therapeutics and Inc. Grades

In addition to Quality, Momentum and Estimate Revisions, A+ Investor also provides grades for Value and Growth.

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Nurix Therapeutics, Inc., Kymera Therapeutics and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Nurix Therapeutics, Inc., Kymera Therapeutics or Inc. Stock?

Overall, Nurix Therapeutics, Inc. stock has a Momentum Score of 81, Estimate Revisions Score of 63 and Quality Score of 5.

Kymera Therapeutics, Inc. stock has a Momentum Score of 83, Estimate Revisions Score of 50 and Quality Score of 33.

Comparing Nurix Therapeutics, Inc., Kymera Therapeutics and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.